基线血清PD-1或PD-L1升高预测转移性黑色素瘤PD-1抑制治疗不良结局
该研究在222例转移性黑色素瘤患者(发现队列130例,验证队列92例)和38例健康对照中,用夹心ELISA法检测基线血清PD-1和PD-L1浓度。结果显示患者血清PD-1(P=0.0054)和PD-L1(P<0.0001)高于健康对照,且基线PD-1/PD-L1升高与抗PD-1治疗的不良最佳总体反应(BOR)、无进展生存(PFS)和总生存(OS)相关,并在独立验证集中确认。
要点
- 基线血清PD-1/PD-L1升高与抗PD-1治疗的不良BOR、PFS和OS相关。
- PD-1/PD-L1联合标志物在独立多中心验证集中确认可区分抗PD-1治疗结局。
- 血清PD-1/PD-L1是抗PD-1治疗患者PFS和OS的独立预测因素。
核心结论
- 基线血清PD-1和PD-L1可作为预测黑色素瘤患者PD-1抑制治疗结局的生物标志物,并有助于选择PD-1为基础还是BRAF为基础的治療策略。
研究设计与样本
- 研究纳入222例转移性黑色素瘤患者(两个回顾性单中心发现队列n=130,一个前瞻性多中心验证队列n=92)和38例健康对照,用夹心ELISA法检测基线血清PD-1和PD-L1浓度。
主要发现
- 黑色素瘤患者血清PD-1(P=0.0054)和PD-L1(P<0.0001)浓度高于健康对照。
- 基线血清PD-1和PD-L1升高与抗PD-1治疗的不良BOR相关(P=0.014,P=0.041),但与BRAF抑制治疗无关。
- 基线PD-1和PD-L1血清水平与接受抗PD-1治疗患者的PFS(P=0.0081,P=0.053)和OS(P=0.055,P=0.0062)相关,但与BRAF抑制剂治疗患者无关。
- 联合PD-1和PD-L1标志物可区分抗PD-1治疗的有利和不良结局,基线PD-1和/或PD-L1升高与不良BOR(P=0.037)、PFS(P=0.048)和OS(P=0.0098)相关。
- 该联合血清标志物在前瞻性收集的独立多中心验证集中得到确认(BOR,P=0.019;PFS,P=0.038;OS,P=0.022)。
临床怎么用
- 基线血清PD-1/PD-L1检测或有助于预测黑色素瘤患者抗PD-1治疗的疗效和生存,并辅助选择PD-1为基础或BRAF为基础的治療策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Programmed cell death protein 1 (PD-1) checkpoint inhibition has recently advanced to one of the most effective treatment strategies in melanoma. Nevertheless, a considerable proportion of patients show upfront therapy resistance and baseline predictive biomarkers of treatment outcome are scarce. In this study we quantified PD-1 and programmed death-ligand 1 (PD-L1) in baseline sera from melanoma patients in relation to therapy response and survival. PATIENTS AND METHODS: Sera taken at therapy baseline from a total of 222 metastatic melanoma patients (two retrospectively selected monocentric discovery cohorts, n = 130; one prospectively collected multicentric validation cohort, n = 92) and from 38 healthy controls were analyzed for PD-1 and PD-L1 concentration by sandwich enzyme-linked immunosorbent assay. RESULTS: Melanoma patients showed higher serum concentrations of PD-1 (P = 0.0054) and PD-L1 (P < 0.0001) than healthy controls. Elevated serum PD-1 and PD-L1 levels at treatment baseline were associated with an impaired best overall response (BOR) to anti-PD-1 (P = 0.014, P = 0.041), but not to BRAF inhibition therapy. Baseline PD-1 and PD-L1 serum levels correlated with progression-free (PFS; P = 0.0081, P = 0.053) and overall survival (OS; P = 0.055, P = 0.0062) in patients who received anti-PD-1 therapy, but not in patients treated with BRAF inhibitors. By combining both markers, we obtained a strong discrimination between favorable and poor outcome of anti-PD-1 therapy, with elevated baseline serum levels of PD-1 and/or PD-L1 associated with an impaired BOR (P = 0.037), PFS (P = 0.048), and OS (P = 0.0098). This PD-1/PD-L1 combination serum biomarker was confirmed in an independent multicenter validation set of serum samples prospectively collected at baseline of PD-1 inhibition (BOR, P = 0.019; PFS, P = 0.038; OS, P = 0.022). Multivariable Cox regression demonstrated serum PD-1/PD-L1 as an independent predictor of PFS (P = 0.010) and OS (P = 0.003) in patients treated with PD-1 inhibitors. CONCLUSION: Our findings indicate PD-1 and PD-L1 as useful serum biomarkers to predict the outcome of PD-1 inhibition therapy in melanoma patients and to select patients for PD-1-based versus BRAF-based therapy strategies.
引用
- Ugurel S, Schadendorf D, Horny K, et al. Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma. Ann Oncol. 2020. PMID: 31912789. doi:10.1016/j.annonc.2019.09.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。